AxoGen reports Q2 adjusted EPS 5c, consensus (4c)

Reports Q2 revenue $47.9M, consensus $43.39M. “We are pleased with our strong revenue growth, bottom line performance and overall results this quarter as we continue to execute on our commercial strategy to drive focus in high potential accounts and increase sales rep productivity,” commented Karen Zaderej, Chairman, CEO, and President of Axogen, Inc. “This aligns with our goal of leveraging top-line growth to improve profitability and cash flow. Additionally, we’ve successfully initiated the rolling submission process of our Biologics License Application for Avance Nerve Graft with FDA and continue to expect to complete the submission in the third quarter.”